search
Back to results

Metabolic Diet for Relapse Prevention in Anorexia Nervosa

Primary Purpose

Anorexia Nervosa

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Metabolic Diet
Sponsored by
Icahn School of Medicine at Mount Sinai
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Anorexia Nervosa focused on measuring anorexia nervosa, metabolic diet, weight-restored, eating disorders

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female
  • Age at least 18 and not over 40
  • BMI at or above 18.5 kg/m2
  • Speaks English
  • Medically stable, as cleared by a licensed physician, with vital signs and initial blood draws
  • History of DSM-5 diagnosis of Anorexia Nervosa (WR-AN only)
  • Weight-restored from underweight BMI (under 18.5 kg/m2) within the past 6 months (WR-AN only)

Exclusion Criteria:

  • Current/lifetime diagnosis of DSM-5 psychotic disorders, bipolar disorders
  • Active DSM-5 substance use disorders
  • On medications that could affect metabolism

    *Subjects are to be free of any medications that could affect metabolism, as discussed with study physician, for 2 weeks prior to primary study visit for glucose function testing.

  • History of suicide attempt within previous 6 months or acute suicide risk
  • Significant current medical illness or metabolic conditions, including diabetes mellitus and pregnancy
  • Current/lifetime diagnosis of DSM-5 eating disorders (HC only)
  • Active DSM-5 depressive disorders (HC only)

Sites / Locations

  • Icahn School of Medicine at Mount SinaiRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Women with anorexia nervosa

Women with no history of eating disorders

Arm Description

adult women with anorexia nervosa who have been recently restored to normal weight

adult women with no history of eating disorders

Outcomes

Primary Outcome Measures

Number of adverse events
Safety of intervention will be measured by # of adverse events reported over 10 weeks. Adverse events will be documented during each of the 8 weekly clinician visits.
Percent completion of food
Tolerability of intervention will be measured using percent completion of food over 10 weeks. Logs are collected during each of the 8 weekly clinician visits.
Percent completion of ketone logs
Tolerability of intervention will be measured using percent completion of ketone logs over 10 weeks. Logs are collected during each of the 8 weekly clinician visits.

Secondary Outcome Measures

Change in Weight
Weight will be calculated using the baseline weight and weight at the 10 week assessment. Weight will be during each of the 8 weekly clinician visits.
Change in Eating Disorder Examination Questionnaire (EDE-Q)
Changes in Dietary Behavior using the Eating Disorder Examination Questionnaire (EDE-Q). Dietary restraint, eating, shape, and weight concerns are measured with the EDE-Q at multiple time points. Subscales for dietary restraint, eating, shape, and weight (subscales range from 0-6) concerns are summed and then divided by the total number of subscales (4) to create a global score (total scale 0 to 6). Higher scores on the global scale and subscales indicate more problematic eating behaviors and attitudes. Changes in the EDE-Q global score will be calculated using the baseline and 10 week assessments.
Changes in Anxiety using the Beck Anxiety Inventory (BAI)
The intensity and physical symptoms of anxiety are measures with the BAI at baseline and 10 weeks. Scores may range from 0 to 63. Higher scores indicate more intense anxiety symptoms. Changes in the BAI score will be calculated using the baselines and 10 week assessments.
Changes in Mood using the Quick Inventory of Depressive Symptomatology (QIDS)
Depression is measured with the QIDS at baseline and 10 weeks. Scores may range from 0 to 27. Higher scores indicate a higher severity of depression. Changes in the QIDS score will be calculated using the baselines and 10 week assessments.
Changes in Clinical Impairments using the Clinical Impairment Assessment (CIA)
Psychosocial functioning from eating disorders is measured using the CIA. Scores range from 0 to 48. Higher scores indicate more impairment associated with an eating disorder.
Changes in Quality of Life using the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) from Baseline to 10 Weeks
Quality of life is measured using the QLESQ. Scores range from 14 to 70 and higher scores indicate a quality.
Changes in Carbon Dioxide (CO2)
The laboratory test to measure the amount of carbon dioxide in the liquid part of the blood, called the serum. In the body, most of the CO2 is in the form of a substance called bicarbonate (HCO3-). Therefore, the CO2 blood test is really a measure of the blood bicarbonate level.
Changes in Potassium level
Potassium test measures the amount of potassium in the fluid portion (serum) of the blood. Potassium (K+) helps nerves and muscles communicate. It also helps move nutrients into cells and waste products out of cells.
Changes in Sodium level
The sodium blood test measures the concentration of sodium in the blood.
Changes in Chloride
Chloride is a type of electrolyte. It works with other electrolytes such as potassium, sodium, and carbon dioxide (CO2). These substances help keep the proper balance of body fluids and maintain the body's acid-base balance.
Changes in Calcium
The calcium blood test measures the level of calcium in the blood. All cells need calcium in order to work. Calcium helps build strong bones and teeth. It is important for heart function, and helps with muscle contraction, nerve signaling, and blood clotting.
Changes in Creatine
The creatinine blood test measures the level of creatinine in the blood. Creatinine is a chemical waste product of creatine. Creatine is a chemical made by the body and is used to supply energy mainly to muscles. This test is done to see how well your kidneys work. Creatinine is removed from the body entirely by the kidneys. If kidney function is not normal, the creatinine level in your blood will increase. This is because less creatinine is excreted through your urine.
Changes in Blood Urea Nitrogen (BUN)
Urea nitrogen is what forms when protein breaks down. The BUN test measures the amount of urea nitrogen in the blood and is often done to check kidney function.
Changes in White Blood Count (WBC)
WBC count is a blood test to measure the number of white blood cells (WBCs) in the blood. WBCs are also called leukocytes. They help fight infections.
Changes in Red Blood Count (RBC)
An RBC count is a blood test that measures amount of red blood cells (RBCs). RBCs contain hemoglobin, which carries oxygen. How much oxygen the body tissues get depends on amount of RBCs and how well they work.
Changes in Hemoglobin
Hemoglobin is a protein in red blood cells that carries oxygen. The hemoglobin test measures how much hemoglobin is in your blood.
Changes in Hematocrit
Hematocrit is a blood test that measures how much of a person's blood is made up of red blood cells. This measurement depends on the number of and size of the red blood cells.
Changes in Platelet
A platelet count is a lab test to measure how many platelets is in the blood. Platelets are parts of the blood that help the blood clot. They are smaller than red or white blood cells.
Changes in hemoglobin A1c
A1C is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well a person is controlling your blood sugar to help prevent complications from diabetes.
Changes in Glucose
A blood sugar test measures the amount of a sugar called glucose in the blood. Glucose is a major source of energy for most cells of the body, including brain cells. Glucose is a building block for carbohydrates. Carbohydrates are quickly turned into glucose in the body. This can raise the blood glucose level. Hormones made in the body help control blood glucose level.
Changes in Total Cholesterol
Cholesterol is a fat (also called a lipid) that your body needs to work properly. Too much bad cholesterol can increase your chance of getting heart disease, stroke, and other problems.
Changes in High density lipoprotein (HDL cholesterol)
HDL is one of the three main types of lipoproteins and part of the lipid panel.
Changes in Low density lipoprotein (LDL cholesterol)
LDL is one of the three main types of lipoproteins and part of the lipid panel.
Changes in Triglycerides
The triglyceride level is a blood test to measure the amount of triglycerides in the blood. Triglycerides are a type of fat.
Changes in aspartate aminotransferase (AST)
The aspartate aminotransferase (AST) blood test measures the level of the enzyme AST in the blood. AST is an enzyme found in high levels in the liver, heart, and muscles. It is also found in lesser amounts in other tissues. An enzyme is a protein that causes a specific chemical change in the body.
Changes in alanine transaminase (ALT)
The alanine transaminase (ALT) blood test measures the level of the enzyme ALT in the blood. ALT is an enzyme found in a high level in the liver. An enzyme is a protein that causes a specific chemical change in the body.
Changes in albumin
Albumin is a protein made by the liver. A serum albumin test measures the amount of this protein in the clear liquid portion of the blood.

Full Information

First Posted
December 16, 2021
Last Updated
June 14, 2023
Sponsor
Icahn School of Medicine at Mount Sinai
search

1. Study Identification

Unique Protocol Identification Number
NCT05197309
Brief Title
Metabolic Diet for Relapse Prevention in Anorexia Nervosa
Official Title
Metabolic Diet for Relapse Prevention in Anorexia Nervosa
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 20, 2022 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Icahn School of Medicine at Mount Sinai

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an interventional study that will test the safety, tolerability, and efficacy of the Metabolic Diet, which was designed as a treatment for women with anorexia nervosa to remain weight-stable after they have been restored from low weight. Participants will be adult women with anorexia nervosa who have been recently restored to normal weight and adult women with no history of eating disorders. After enrollment, participants will start meeting weekly with a registered dietitian to implement the Metabolic Diet in their daily lives, and will receive medical monitoring for adherence, side effects, changes in metabolic or psychological parameters, and weight stability.
Detailed Description
The study plan to enroll a total of 20 subjects from the broader New York City area into an 8-week eating behavioral program. Of the 20, 10 will be weight-restored patients with anorexia nervosa (WR-AN) and the other 10 will be age-, sex-, and body mass index (i.e. weight) matched healthy controls (HC). The primary study intervention is an eating behavioral program called, Metabolic Diet, which is aimed to change the proportion of macronutrients in their meals to incorporate higher fat content and lower the carbohydrate content to limit fluctuations in circulating blood glucose levels throughout the day, which may contribute to a relapse in anorexia nervosa. Participants will be guided to start the Metabolic Diet following the first 2 individual study visits, and the duration of the primary intervention is for 8 weeks. As part of the intervention, each subject will keep a food log and measure the urinary ketones at home, which they will discuss with the study providers during weekly visits. Each subject will meet individually with the Study Dietician and with the Study Physician on a weekly basis. At these visits, food logs and ketone logs will be reviewed so that subjects' adherence to the Metabolic Diet can be assessed and facilitated. Surveys and lab work are completed during screening, week 4 and week 8.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anorexia Nervosa
Keywords
anorexia nervosa, metabolic diet, weight-restored, eating disorders

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
All participants will complete 8 weeks of the Metabolic Diet while meeting with a clinician weekly.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Women with anorexia nervosa
Arm Type
Active Comparator
Arm Description
adult women with anorexia nervosa who have been recently restored to normal weight
Arm Title
Women with no history of eating disorders
Arm Type
Active Comparator
Arm Description
adult women with no history of eating disorders
Intervention Type
Dietary Supplement
Intervention Name(s)
Metabolic Diet
Intervention Description
Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.
Primary Outcome Measure Information:
Title
Number of adverse events
Description
Safety of intervention will be measured by # of adverse events reported over 10 weeks. Adverse events will be documented during each of the 8 weekly clinician visits.
Time Frame
10 weeks
Title
Percent completion of food
Description
Tolerability of intervention will be measured using percent completion of food over 10 weeks. Logs are collected during each of the 8 weekly clinician visits.
Time Frame
10 weeks
Title
Percent completion of ketone logs
Description
Tolerability of intervention will be measured using percent completion of ketone logs over 10 weeks. Logs are collected during each of the 8 weekly clinician visits.
Time Frame
Baseline to 10 weeks
Secondary Outcome Measure Information:
Title
Change in Weight
Description
Weight will be calculated using the baseline weight and weight at the 10 week assessment. Weight will be during each of the 8 weekly clinician visits.
Time Frame
Baseline and 10 weeks
Title
Change in Eating Disorder Examination Questionnaire (EDE-Q)
Description
Changes in Dietary Behavior using the Eating Disorder Examination Questionnaire (EDE-Q). Dietary restraint, eating, shape, and weight concerns are measured with the EDE-Q at multiple time points. Subscales for dietary restraint, eating, shape, and weight (subscales range from 0-6) concerns are summed and then divided by the total number of subscales (4) to create a global score (total scale 0 to 6). Higher scores on the global scale and subscales indicate more problematic eating behaviors and attitudes. Changes in the EDE-Q global score will be calculated using the baseline and 10 week assessments.
Time Frame
Baseline and 10 weeks
Title
Changes in Anxiety using the Beck Anxiety Inventory (BAI)
Description
The intensity and physical symptoms of anxiety are measures with the BAI at baseline and 10 weeks. Scores may range from 0 to 63. Higher scores indicate more intense anxiety symptoms. Changes in the BAI score will be calculated using the baselines and 10 week assessments.
Time Frame
Baseline and 10 weeks
Title
Changes in Mood using the Quick Inventory of Depressive Symptomatology (QIDS)
Description
Depression is measured with the QIDS at baseline and 10 weeks. Scores may range from 0 to 27. Higher scores indicate a higher severity of depression. Changes in the QIDS score will be calculated using the baselines and 10 week assessments.
Time Frame
Baseline and 10 weeks
Title
Changes in Clinical Impairments using the Clinical Impairment Assessment (CIA)
Description
Psychosocial functioning from eating disorders is measured using the CIA. Scores range from 0 to 48. Higher scores indicate more impairment associated with an eating disorder.
Time Frame
Baseline and 10 weeks
Title
Changes in Quality of Life using the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) from Baseline to 10 Weeks
Description
Quality of life is measured using the QLESQ. Scores range from 14 to 70 and higher scores indicate a quality.
Time Frame
Baseline and 10 weeks
Title
Changes in Carbon Dioxide (CO2)
Description
The laboratory test to measure the amount of carbon dioxide in the liquid part of the blood, called the serum. In the body, most of the CO2 is in the form of a substance called bicarbonate (HCO3-). Therefore, the CO2 blood test is really a measure of the blood bicarbonate level.
Time Frame
Baseline and 10 weeks
Title
Changes in Potassium level
Description
Potassium test measures the amount of potassium in the fluid portion (serum) of the blood. Potassium (K+) helps nerves and muscles communicate. It also helps move nutrients into cells and waste products out of cells.
Time Frame
Baseline and 10 weeks
Title
Changes in Sodium level
Description
The sodium blood test measures the concentration of sodium in the blood.
Time Frame
Baseline and 10 weeks
Title
Changes in Chloride
Description
Chloride is a type of electrolyte. It works with other electrolytes such as potassium, sodium, and carbon dioxide (CO2). These substances help keep the proper balance of body fluids and maintain the body's acid-base balance.
Time Frame
Baseline and 10 weeks
Title
Changes in Calcium
Description
The calcium blood test measures the level of calcium in the blood. All cells need calcium in order to work. Calcium helps build strong bones and teeth. It is important for heart function, and helps with muscle contraction, nerve signaling, and blood clotting.
Time Frame
Baseline and 10 weeks
Title
Changes in Creatine
Description
The creatinine blood test measures the level of creatinine in the blood. Creatinine is a chemical waste product of creatine. Creatine is a chemical made by the body and is used to supply energy mainly to muscles. This test is done to see how well your kidneys work. Creatinine is removed from the body entirely by the kidneys. If kidney function is not normal, the creatinine level in your blood will increase. This is because less creatinine is excreted through your urine.
Time Frame
Baseline and 10 weeks
Title
Changes in Blood Urea Nitrogen (BUN)
Description
Urea nitrogen is what forms when protein breaks down. The BUN test measures the amount of urea nitrogen in the blood and is often done to check kidney function.
Time Frame
Baseline and 10 weeks
Title
Changes in White Blood Count (WBC)
Description
WBC count is a blood test to measure the number of white blood cells (WBCs) in the blood. WBCs are also called leukocytes. They help fight infections.
Time Frame
Baseline and 10 weeks
Title
Changes in Red Blood Count (RBC)
Description
An RBC count is a blood test that measures amount of red blood cells (RBCs). RBCs contain hemoglobin, which carries oxygen. How much oxygen the body tissues get depends on amount of RBCs and how well they work.
Time Frame
Baseline and 10 weeks
Title
Changes in Hemoglobin
Description
Hemoglobin is a protein in red blood cells that carries oxygen. The hemoglobin test measures how much hemoglobin is in your blood.
Time Frame
Baseline and 10 weeks
Title
Changes in Hematocrit
Description
Hematocrit is a blood test that measures how much of a person's blood is made up of red blood cells. This measurement depends on the number of and size of the red blood cells.
Time Frame
Baseline and 10 weeks
Title
Changes in Platelet
Description
A platelet count is a lab test to measure how many platelets is in the blood. Platelets are parts of the blood that help the blood clot. They are smaller than red or white blood cells.
Time Frame
Baseline and 10 weeks
Title
Changes in hemoglobin A1c
Description
A1C is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well a person is controlling your blood sugar to help prevent complications from diabetes.
Time Frame
Baseline and 10 weeks
Title
Changes in Glucose
Description
A blood sugar test measures the amount of a sugar called glucose in the blood. Glucose is a major source of energy for most cells of the body, including brain cells. Glucose is a building block for carbohydrates. Carbohydrates are quickly turned into glucose in the body. This can raise the blood glucose level. Hormones made in the body help control blood glucose level.
Time Frame
Baseline and 10 weeks
Title
Changes in Total Cholesterol
Description
Cholesterol is a fat (also called a lipid) that your body needs to work properly. Too much bad cholesterol can increase your chance of getting heart disease, stroke, and other problems.
Time Frame
Baseline and 10 weeks
Title
Changes in High density lipoprotein (HDL cholesterol)
Description
HDL is one of the three main types of lipoproteins and part of the lipid panel.
Time Frame
Baseline and 10 weeks
Title
Changes in Low density lipoprotein (LDL cholesterol)
Description
LDL is one of the three main types of lipoproteins and part of the lipid panel.
Time Frame
Baseline and 10 weeks
Title
Changes in Triglycerides
Description
The triglyceride level is a blood test to measure the amount of triglycerides in the blood. Triglycerides are a type of fat.
Time Frame
Baseline and 10 weeks
Title
Changes in aspartate aminotransferase (AST)
Description
The aspartate aminotransferase (AST) blood test measures the level of the enzyme AST in the blood. AST is an enzyme found in high levels in the liver, heart, and muscles. It is also found in lesser amounts in other tissues. An enzyme is a protein that causes a specific chemical change in the body.
Time Frame
Baseline and 10 weeks
Title
Changes in alanine transaminase (ALT)
Description
The alanine transaminase (ALT) blood test measures the level of the enzyme ALT in the blood. ALT is an enzyme found in a high level in the liver. An enzyme is a protein that causes a specific chemical change in the body.
Time Frame
Baseline and 10 weeks
Title
Changes in albumin
Description
Albumin is a protein made by the liver. A serum albumin test measures the amount of this protein in the clear liquid portion of the blood.
Time Frame
Baseline and 10 weeks

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female Age at least 18 and not over 40 BMI at or above 18.5 kg/m2 Speaks English Medically stable, as cleared by a licensed physician, with vital signs and initial blood draws History of DSM-5 diagnosis of Anorexia Nervosa (WR-AN only) Weight-restored from underweight BMI (under 18.5 kg/m2) within the past 6 months (WR-AN only) Exclusion Criteria: Current/lifetime diagnosis of DSM-5 psychotic disorders, bipolar disorders Active DSM-5 substance use disorders On medications that could affect metabolism *Subjects are to be free of any medications that could affect metabolism, as discussed with study physician, for 2 weeks prior to primary study visit for glucose function testing. History of suicide attempt within previous 6 months or acute suicide risk Significant current medical illness or metabolic conditions, including diabetes mellitus and pregnancy Current/lifetime diagnosis of DSM-5 eating disorders (HC only) Active DSM-5 depressive disorders (HC only)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tom Hildebrandt
Phone
212-659-8673
Email
tom.hildebrandt@mssm.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Chinara Tate
Phone
212-659-8724
Email
chinara.tate@mssm.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tom Hildebrandt
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tom Hildebrandt
Phone
212-659-8673
Email
tom.hildebrandt@mssm.edu
First Name & Middle Initial & Last Name & Degree
Chinara Tate
Phone
212-659-8724
Email
chinara.tate@mssm.edu
First Name & Middle Initial & Last Name & Degree
Tom Hildebrandt

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Anonymized data can be made available upon request.

Learn more about this trial

Metabolic Diet for Relapse Prevention in Anorexia Nervosa

We'll reach out to this number within 24 hrs